HIV protease and HIV integrase — Drug Target

All drugs that target HIV protease and HIV integrase — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Antiretroviral combination (protease inhibitor + integrase inhibitor) · Protease inhibitor and integrase strand transfer inhibitor

Marketed (1)

• atazanavir/raltegravir · Community Research Initiative of New England · Antiretroviral combination (protease inhibitor + integrase inhibitor) · Infectious Disease
  This combination blocks HIV protease and integrase enzymes to prevent viral replication and reduce viral load in HIV-infected patients.

Phase 3 pipeline (1)

• darunavir/ritonavir QD + raltegravir BID · ANRS, Emerging Infectious Diseases · Protease inhibitor and integrase strand transfer inhibitor · Infectious Diseases
  Darunavir/ritonavir QD is a protease inhibitor that blocks HIV replication, while raltegravir BID is an integrase strand transfer inhibitor that also blocks HIV replication.